PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) was upgraded by analysts at CLSA to a "strong-buy" rating.
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $6.00 price target on the stock.
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights